A recent survey of 15 Wall Street analysts reveals an average price target implying a 26.42% upside for West Pharmaceutical over the next 12 months. Analysts cited continued strength in injectable drug delivery systems and expanding capacity in high-barrier markets such as biologics and specialty oncology. Five analysts raised their targets in the past month, reflecting increased confidence in West’s market share gains against smaller contract manufacturers. The highest individual target suggests a potential gain of more than 30%, while the most conservative still anticipates roughly a 15% rise, underscoring broad-based optimism among institutional researchers.

Over the last quarter, consensus earnings estimates for West Pharmaceutical have been revised upward by an average of 4.8%. Nine analysts increased their full-year EPS forecasts, citing stronger-than-expected order backlogs and improved margin leverage from recent capacity investments in the U.S. and Europe. Revenue estimates for the current fiscal year climbed by 3.2%, driven by accelerated contract wins in prefilled syringe systems and on-body injector platforms. The ratio of upward-to-downward revisions stands at 3.5-to-1, one of the highest readings in the specialty pharma equipment space, signaling that upward momentum in fundamentals may underpin further stock appreciation.